Get the Stockscreener App
19.40
1.61%
-0.3323
Apellis Pharmaceuticals Inc stock is traded at $19.40, with a volume of 816.97K.
It is down -1.61% in the last 24 hours and down -20.83% over the past month.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
See More
Previous Close:
$19.73
Open:
$19.61
24h Volume:
816.97K
Relative Volume:
0.33
Market Cap:
$2.50B
Revenue:
$715.22M
Net Income/Loss:
$-250.10M
P/E Ratio:
-9.5555
EPS:
-2.03
Net Cash Flow:
$-205.58M
1W Performance:
-3.04%
1M Performance:
-20.83%
6M Performance:
+9.86%
1Y Performance:
-33.04%
1-Day Range:
$19.38
$19.83
1-Week Range:
$19.38
$20.70
52-Week Range:
$16.10
$35.72
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Name
Apellis Pharmaceuticals Inc
Sector
Industry
Phone
617-977-5700
Address
100 FIFTH AVENUE, WALTHAM, KY
Compare APLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
19.39 | 2.50B | 715.22M | -250.10M | -205.58M | -2.03 |
|
ARGX
Argen X Se Adr
|
917.05 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
201.28 | 43.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.08 | 110.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ONC
Beone Medicines Ltd Adr
|
355.60 | 40.27B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
709.22 | 76.23B | 14.25B | 4.58B | 3.88B | 41.77 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-25 | Initiated | Wolfe Research | Peer Perform |
| Oct-15-25 | Initiated | Wells Fargo | Overweight |
| Sep-26-25 | Downgrade | Goldman | Neutral → Sell |
| May-09-25 | Downgrade | BofA Securities | Buy → Neutral |
| May-09-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-17-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-21-24 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-25-24 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-16-24 | Initiated | William Blair | Outperform |
| May-31-24 | Initiated | Piper Sandler | Neutral |
| Feb-05-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-02-23 | Initiated | Mizuho | Neutral |
| Oct-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-29-23 | Reiterated | Citigroup | Buy |
| Aug-03-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-01-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-10-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-19-22 | Initiated | H.C. Wainwright | Buy |
| Jun-17-22 | Resumed | Stifel | Buy |
| Apr-14-22 | Downgrade | ROTH Capital | Neutral → Sell |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-29-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-10-21 | Reiterated | BMO Capital Markets | Outperform |
| Sep-10-21 | Reiterated | Credit Suisse | Neutral |
| Sep-10-21 | Reiterated | Needham | Buy |
| Sep-10-21 | Reiterated | Oppenheimer | Outperform |
| Sep-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Aug-19-21 | Initiated | Jefferies | Buy |
| Aug-19-21 | Upgrade | Wedbush | Neutral → Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Nov-19-20 | Initiated | Needham | Buy |
| Sep-01-20 | Initiated | Stifel | Buy |
| Jul-20-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| Apr-01-20 | Initiated | Raymond James | Strong Buy |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-11-20 | Upgrade | Wedbush | Underperform → Neutral |
| Jan-07-20 | Initiated | SVB Leerink | Mkt Perform |
| Dec-19-19 | Initiated | BofA/Merrill | Buy |
| Nov-22-19 | Initiated | Wedbush | Underperform |
| Nov-05-19 | Initiated | Credit Suisse | Neutral |
| Aug-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-30-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| May-24-18 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Apellis Pharmaceuticals Inc Stock (APLS) Latest News
Will Apellis Pharmaceuticals Inc. stock deliver better than expected guidance2025 Market Overview & Low Drawdown Momentum Ideas - newser.com
Risk vs reward if holding onto Apellis Pharmaceuticals Inc.2025 Top Gainers & Stepwise Trade Signal Implementation - newser.com
Why Apellis Pharmaceuticals Inc. (1JK) stock stays on buy listsWeekly Investment Recap & Fast Exit and Entry Strategy Plans - newser.com
Published on: 2025-11-19 03:53:39 - newser.com
Can Apellis Pharmaceuticals Inc. stock resist sector downturnsMarket Weekly Review & AI Driven Price Predictions - newser.com
Can Apellis Pharmaceuticals Inc. stock beat analyst upgradesMarket Activity Report & Safe Capital Allocation Plans - newser.com
Using AI based signals to follow Apellis Pharmaceuticals Inc.Market Sentiment Report & Free Technical Confirmation Trade Alerts - newser.com
Will Apellis Pharmaceuticals Inc. see short term momentum2025 Market Overview & AI Forecast for Swing Trade Picks - newser.com
Apellis Pharma general counsel Watson sells $100k in stock By Investing.com - Investing.com Canada
Apellis Pharma general counsel Watson sells $100k in stock - Investing.com
Why Apellis Pharmaceuticals Inc. (1JK) stock could rally strongly2025 Bull vs Bear & Smart Money Movement Alerts - newser.com
Why Apellis Pharmaceuticals Inc. stock is rated strong buyJuly 2025 Opening Moves & Technical Pattern Alert System - newser.com
Apellis Pharmaceuticals (BIT:1APLS) Price Target Decreased by 10.35% to 30.35 - Nasdaq
How Apellis Pharmaceuticals Inc. stock performs in weak economy2025 Growth vs Value & Fast Exit and Entry Strategy Plans - newser.com
What high frequency data says about Apellis Pharmaceuticals Inc.2025 Earnings Impact & Weekly High Momentum Picks - newser.com
Will breakout in Apellis Pharmaceuticals Inc. lead to full recovery2025 Short Interest & Real-Time Volume Triggers - newser.com
(APLS) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
How to build a dashboard for Apellis Pharmaceuticals Inc. stockVolume Spike & Free Daily Entry Point Trade Alerts - newser.com
Does Apellis Pharmaceuticals Inc. (1JK) stock trade below intrinsic valueJuly 2025 Highlights & AI Based Buy/Sell Signal Reports - newser.com
Will Apellis Pharmaceuticals Inc. stock gain from lower inflationJuly 2025 Volume & Fast Gaining Stock Reports - newser.com
Apellis Pharmaceuticals Inc. stock prediction for this weekJuly 2025 Technicals & Expert Curated Trade Setup Alerts - newser.com
How interest rate cuts could boost Apellis Pharmaceuticals Inc. stockJuly 2025 Outlook & Stepwise Entry/Exit Trade Alerts - newser.com
Published on: 2025-11-14 10:40:48 - newser.com
Published on: 2025-11-13 18:42:44 - newser.com
Regression analysis insights on Apellis Pharmaceuticals Inc. performanceTreasury Yields & AI Forecasted Stock Moves - newser.com
Can Apellis Pharmaceuticals Inc. stock sustain market leadershipQuarterly Growth Report & High Accuracy Buy Signal Tips - newser.com
Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years - BioSpace
Is Five-Year SYFOVRE Data Shifting the Investment Case for Apellis Pharmaceuticals (APLS)? - Yahoo Finance
Apellis Pharmaceuticals Inc Stock (APLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):